



Viral Epidemiology Snapshot: January 9-15, 2022

Prepared by Anne Hall, Ph.D., M(ASCP) on behalf of the Molecular Diagnostics/Virology Labs

CoV-2, Flu, & RSV

Virus	#Tested	#Positive	% Positive
Flu A	712	16	2.2%
Flu B	712	3	0.4%
RSV	553	24	4.3%
CoV-2 PUI	3028	997	32.9%
CoV-2 Surveillance	438	41	9.4%


Flu A Subtyping

2009 H1N1	0
Seasonal H1	0
Seasonal H3	4
No Subtype	12
Pending subtype	0

Other Respiratory Viruses

Virus	#Tested	#Positive	% Positive
Adenovirus	549	40	7.3%
Coronavirus 229E	549	5	0.9%
Coronavirus HKU1	549	0	0.0%
Coronavirus NL63	549	0	0.0%
Coronavirus OC43	549	25	4.6%
Metapneumovirus	549	82	14.9%
Rhinovirus/Enterovirus	549	81	14.8%
Parainfluenza 1	549	0	0.0%
Parainfluenza 2	549	2	0.4%
Parainfluenza 3	549	8	1.5%
Parainfluenza 4	549	7	1.3%

Flu, RSV, & CoV-2 Trends




This report contains results for molecular and antigen tests ordered throughout the CHMCA network and performed at the Akron/Mahoning valley laboratories.

As of 11/14, this report also includes Point-of-Care tests (POCT) for influenza performed at ACHP locations.

Notes on Influenza A subtyping: Influenza A found by the Respiratory Film Array test will also include a subtype. Influenza A found by POCT methods will be listed as "no subtype".

CoV-2 Positivity Rate Trends



Notes on SARS-CoV-2 data: In the top chart, the red CoV-2 line traces the total number of patients testing positive each week. In the bottom chart, the orange line ("PUI") shows data for all patients with symptoms or known exposures ("Patient Under Investigation") while the purple line ("Surv.") shows surveillance data for undergoing pre-procedure screening.

As of 10/31, the surveillance line shows patients who have been designated as "pre-procedure" in their testing order questionnaire, as well as participants in the employee screening program.

